


## SYNTHESIS OF NOVEL HETEROCYCLIC SYSTEM – IMIDAZO[5,1-*b*][1,3]BENZOXAZINE

V. A. Osyanin<sup>1</sup> and N. E. Sidorina<sup>2</sup>

**Keywords:** 2-hydroxymethylphenols, imidazo[5,1-*b*][1,3]benzoxazines, 4-iodo-2-methyl-5-nitroimidazole, *o*-methylenequinones

There is no information in the literature about the synthesis of compounds containing the condensed imidazo[5,1-*b*][1,3]benzoxazine system. At the same time, the high biological activity of many imidazole and benzoxazine derivatives serves as a stimulus to synthesize condensed heterocycles containing both of these fragments simultaneously [1-3].

We propose a simple, one stage method for preparing the substituted imidazo[5,1-*b*][1,3]benzoxazines **1**, **2** consisting of the reaction of 4-iodo-2-methyl-5-nitroimidazole with substituted 2-hydroxymethylphenols through refluxing in DMF.



The reaction takes place *via* the intermediate stage of forming an *o*-methylenequinone (*o*-quinonemethide) [4] which attacks the imidazole molecule to form a substituted 2-(1H-imidazol-1-ylmethyl)phenol and then undergoes an intramolecular cyclization with release of an HI molecule.

<sup>1</sup>Samara State Technical University, Samara 443100, Russia, e-mail: vosyanin@mail.ru. <sup>2</sup>Samara State University, Samara 443011, Russia, e-mail: sidorinan@inbox.ru. Translated from *Khimiya Geterotsiklicheskikh Soedinenii*, No. 11, pp. 1741-1742, November, 2006. Original article submitted September 12, 2006.

IR spectra were recorded on a Shimadzu FTIR-8400S spectrophotometer using KBr tablets. <sup>1</sup>H NMR spectra were taken on a Bruker AM 300 spectrometer (300 MHz) using DMSO-d<sub>6</sub> and with TMS as internal standard. Mass spectra were recorded on a Finnigan Trance DSQ chromatographic mass spectrometer with direct introduction of the sample into the ion source.

**7-Bromo-1-methyl-3-nitro-9H-imidazo[5,1-b][1,3]benzoxazine (1).** A mixture of 4-iodo-2-methyl-5-nitroimidazole (1.0 g, 4 mmol) and 4-bromo-2-hydroxymethylphenol (0.84 g, 4.14 mmol) in DMF (10 ml) was heated at 125-130°C for 3 h and then at reflux for 3 h. The mixture was cooled, poured into water, the precipitate filtered off, and crystallized from DMF to give compound **1** (0.81 g, 66%) as colorless crystals with mp 275-277°C. IR spectrum,  $\nu$ , cm<sup>-1</sup>: 3047 (CH<sub>arom</sub>), 2924, 2854 (CH<sub>3</sub>), 1620, 1597, 1578 (C=C/C=N), 1477, 1377, 1350, 1269, 1234, 1173, 1115, 1088 (C-O-C). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm (*J*, Hz): 2.36 (3H, s, CH<sub>3</sub>); 5.26 (2H, s, CH<sub>2</sub>); 7.33 (1H, d, *J* = 8.8, H-5); 7.60 (1H, d, *J* = 8.8, H-6); 7.67 (1H, s, H-8). Mass spectrum, (EI, 70 eV, for <sup>79</sup>Br isotope), *m/z* (*I*<sub>rel</sub>, %): 309 [M]<sup>+</sup> (98); 263 [M-NO<sub>2</sub>]<sup>+</sup> (5), 238 (11), 210 (31), 184 [C<sub>7</sub>H<sub>5</sub>BrO]<sup>+</sup> (12), 156 [C<sub>6</sub>H<sub>5</sub>Br]<sup>+</sup> (14), 77 [C<sub>6</sub>H<sub>5</sub>]<sup>+</sup> (32), 51 (15), 43 [HNCO]<sup>+</sup> (78). Found %: C 42.71; H 2.54; N 13.22. C<sub>11</sub>H<sub>8</sub>BrN<sub>3</sub>O<sub>3</sub>. Calculated, %: C 42.58; H 2.58; N 13.55.

**1-Methyl-3,7-dinitro-9H-imidazo[5,1-b][1,3]benzoxazine (2)** was prepared similarly to compound **1** from 4-iodo-2-methyl-5-nitroimidazole (1.14 g, 4.5 mmol) and 2-hydroxymethyl-4-nitrophenol (0.81 g, 4.8 mmol) as pink crystals with mp 302-303°C (with decomp.) (from DMF) in 0.63 g (51%) yield. IR Spectrum,  $\nu$ , cm<sup>-1</sup>: 3040 (CH<sub>arom</sub>), 2928, 2858 (CH<sub>3</sub>), 1601, 1578 (C=C/C=N), 1531 (NO<sub>2</sub>), 1477, 1389, 1342 (NO<sub>2</sub>), 1281, 1258, 1227, 1184, 1088 (C-O-C). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm (*J*, Hz): 2.40 (3H, s, CH<sub>3</sub>); 5.44 (2H, s, CH<sub>2</sub>); 7.38 (1H, d, *J* = 9.1 H-5); 7.87 (1H, d, *J* = 9.1, H-6); 8.01 (1H, s, H-8). Mass spectrum, (EI, 70 eV), *m/z* (*I*<sub>rel</sub>, %): 276 [M]<sup>+</sup> (65), 230 [M-NO<sub>2</sub>]<sup>+</sup> (5), 204 (8), 184 [M-2 NO<sub>2</sub>]<sup>+</sup> (3), 177 (15), 151 [C<sub>7</sub>H<sub>5</sub>NO<sub>3</sub>]<sup>+</sup> (4), 77 [C<sub>6</sub>H<sub>5</sub>]<sup>+</sup> (12), 43 [HNCO]<sup>+</sup> (100). Found, %: C 47.97; H 2.85; N 19.80. C<sub>11</sub>H<sub>8</sub>N<sub>4</sub>O<sub>5</sub>. Calculated, %: C 47.83; H 2.90; N 20.29.

## REFERENCES

1. M. Adib, E. Sheibani, M. Mostofi, K. Ghanbary, and H. R. Bijanzadeh, *Tetrahedron*, **62**, 3435 (2006).
2. J. Muller, S. Reeves, and J. Salaman, *J. Immunopharmacol.*, **2**, 225 (1980).
3. E. S. Charles, K. V. B. Rao, S. Sharma, and R. N. Iyer, *Arch. Pharm.*, **315**, 97 (1982).
4. Van De R. W. Water and T. R. R. Pettus, *Tetrahedron*, **58**, 5367 (2002).